Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry

J Pathol Clin Res. 2021 Oct 14. doi: 10.1002/cjp2.244. Online ahead of print.ABSTRACTThe differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important for the prognosis and therapy of the affected patient. By using high-resolution mass spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 proteins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. Of those, CAV1, CAV2, LGALS1, LGALS7, CK19, and UGDH were tested by immunohistochemistry on 194 tissue samples (98 lung and 96 HNSCCs). The combination of CAV1 and LGALS7 was able to distinguish the origin of the squamous cell carcinoma with high accuracy (area under the curve 0.876). This biomarker panel was tested on a cohort of 12 clinically classified lung tumours of unknown origin after HNSCC. Nine of those tumours were immunohistochemically classifiable.PMID:34647699 | DOI:10.1002/cjp2.244
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

ConclusionOur findings provide a useful picture of mortality patterns in HNSCC survivors, which might help when planning personalized HNSCC care.
Source: Journal of Huazhong University of Science and Technology -- Medical Sciences -- - Category: Research Source Type: research
Leucine Zipper-bearing Kinase (LZK) has been identified as a novel therapeutic target in squamous cell carcinomas with 50% of head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinomas (LSCC) patients showing amplifications or gains in LZK expression. Identifying successful therapies for the treatment of HNSCC or LSCC remains a significant unmet medical need.Researchers at the National Institutes of Health (NIH) have developed novel LZK-targeting ATP-competitive catalytic inhibitors as therapies for treating these two cancer subtypes. They have synthesized LZK-targeting inhibitors that suppresses LZK c...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Licensing Desired & Collaboration Desired Collaboration Sought NCI Source Type: research
ConclusionMYL9 can serve as a prognostic signature in pan-cancer and is associated with immune infiltration. This pan-cancer study is the first to show  a relatively comprehensive understanding of the prognostic and immunological roles of MYL9 across different cancers.
Source: Immunity, Inflammation and Disease - Category: Allergy & Immunology Authors: Tags: SHORT REPORT Source Type: research
J Pathol Clin Res. 2021 Oct 14. doi: 10.1002/cjp2.244. Online ahead of print.ABSTRACTThe differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers but is crucially important for the prognosis and therapy of the affected patient. By using high-resolution mass spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 proteins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
In this study, using established transcriptomic signatures, we identified a group of gene combination associated with favorable outcome in HNSCC linked to a higher presence of immune effector cells. CD2, CD3D, CD3E, and CXCR6 combined gene expression is associated with improved outcome of HNSCC patients and an increase of infiltrating immune effector cells. This new signature also identifies a subset of cervical squamous cell carcinoma (CSCC) patients with favorable prognosis, who show an increased presence of immune effector cells in the tumor, which outcome shows similarities with the HP-positive HNSCC cohort of patients...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Development of immune-related skin rash was found to correlate with favorable outcome, suggesting its practical feasibility as a potential predictive surrogate marker.PMID:34515189 | DOI:10.1159/000518449
Source: Cell Research - Category: Cytology Authors: Source Type: research
Conditions:   Non-Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma Interventions:   Drug: ABBV-514;   Drug: Pembrolizumab;   Drug: Budigalimab Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION AND RELEVANCE: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.PMID:34282636 | DOI:10.1177/10600280211033938
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Lung Cancer | Skin Cancer | Squamous Cell Carcinoma